News about "US FDA Approval"

GSK Receives US FDA Accelerated Approval for Nelkarmi in ALK-Positive Lung Cancer

GSK Receives US FDA Accelerated Approval for Nelkarmi in ALK-Positive Lung Cancer

GSK receives US FDA accelerated approval for Nelkarmi to treat adults with previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer.

US FDA Approval | 19/11/2026 | By News Bureau

Novartis' Cosentyx Receives US FDA Approval for Polymyalgia Rheumatica

Novartis' Cosentyx Receives US FDA Approval for Polymyalgia Rheumatica

Novartis receives US FDA approval for Cosentyx 150 mg to treat adults with polymyalgia rheumatica, making it the first anti-IL-17 biologic approved for the condition.

US FDA Approval | 18/11/2026 | By News Bureau

Alembic Pharmaceuticals Receives USFDA Approval for Binimetinib Tablets

Alembic Pharmaceuticals Receives USFDA Approval for Binimetinib Tablets

Alembic Pharmaceuticals has received final USFDA approval for binimetinib tablets in 15 mg and 45 mg strengths and is eligible for 180 days of generic drug exclusivity.

US FDA Approval | 17/11/2026 | By News Bureau

Biocon Receives US FDA Approval for Pertuzumab Biosimilar Pebrilzo

Biocon Receives US FDA Approval for Pertuzumab Biosimilar Pebrilzo

Biocon receives US FDA approval for Pebrilzo (pertuzumab-qcay), a biosimilar of Perjeta, for HER2-positive breast cancer, marking its fifth FDA-approved oncology biosimilar.

US FDA Approval | 16/11/2026 | By News Bureau

Abbisko Therapeutics Secures US FDA Approval for Pimjetmi to Treat TGCT

Abbisko Therapeutics Secures US FDA Approval for Pimjetmi to Treat TGCT

Abbisko Therapeutics’ Pimjetmi receives US FDA approval as a systemic treatment for adults with symptomatic tenosynovial giant cell tumour.

US FDA Approval | 12/11/2026 | By News Bureau

Alembic Pharmaceuticals Receives US FDA Approval for Olopatadine Eye Drops

Alembic Pharmaceuticals Receives US FDA Approval for Olopatadine Eye Drops

Alembic Pharmaceuticals receives final US FDA approval for its olopatadine hydrochloride ophthalmic solution USP, 0.7 per cent, an OTC treatment for itchy eyes.

US FDA Approval | 05/11/2026 | By News Bureau

FDA Approves Talazoparib with Enzalutamide for Prostate Cancer

FDA Approves Talazoparib with Enzalutamide for Prostate Cancer

The US FDA has approved talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations.

US FDA Approval | 03/11/2026 | By News Bureau

US FDA Approves NRx Pharmaceuticals' Preservative-Free Ketamine

US FDA Approves NRx Pharmaceuticals' Preservative-Free Ketamine

NRx Pharmaceuticals has received the US FDA approval for preservative-free ketamine ahead of the agency’s November 10 goal date.

US FDA Approval | 02/11/2026 | By News Bureau

Alembic Pharma Gets US FDA Approval for Valganciclovir

Alembic Pharma Gets US FDA Approval for Valganciclovir

Alembic Pharmaceuticals has received US FDA final approval for Valganciclovir Oral Solution 50 mg/mL, a generic equivalent of Valcyte by CHEPLAPHARM.

US FDA Approval | 28/10/2026 | By News Bureau

US FDA Approves Novo's Weekly Insulin Awiqli for Children

US FDA Approves Novo's Weekly Insulin Awiqli for Children

Novo’s Awiqli has received US FDA approval as the first and only once-weekly insulin for children aged 10 years and older with Type 2 Diabetes.

US FDA Approval | 24/10/2026 | By News Bureau |  140


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members